Persistent URL of this record https://hdl.handle.net/1887/96289
In Collections
This item can be found in the following collections:
![No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
No evidence for an increased GVHD risk associated with post-transplant Idelalisib given for relapse of chronic lymphocytic leukemia or lymphoma: First results of a survey by the EBMT chronic malignancy and lymphoma working parties
- All authors
- Dreger, P.; Boumendil, A.; Koster, L.; Scheid, C.; Passweg, J.; Veelken, H.; Cahn, Y.; Collin, M.; Wilson, K.; Bazarbachi, A.; Mayer, J.; Corradini, P.; Hunault-Berger, M.; Porras, R.P.; Gribben, J.; Bittenbring, J.; Wolff, D.; Charbonnier, A.; Cambier, N.; Montoto, S.; Kroger, N.; Schetelig, J.
- Date
- 2017-07-31
- Journal
- Bone Marrow Transplantation
- Volume
- 52
- Pages
- S424 - S425